乳腺癌即刻重建局部安全性:直接植入与扩张器法比较
本研究纳入3年内294例乳腺癌即刻乳房重建,比较直接植入(DTI)与扩张器法重建的并发症。DTI组总体并发症17.2%(主要4.3%、次要12.8%),与临床变量无显著关联;扩张器组总体18.3%(主要12.5%、次要5.8%),主要并发症与扩张器大小、BMI及放疗相关。作者认为DTI重建安全。
要点
- DTI重建总体并发症17.2%,主要并发症仅4.3%,未见与临床变量的显著关联
- 扩张器重建主要并发症12.5%,与扩张器大小、BMI、放疗相关
- 放疗与BMI在多因素分析中仍为扩张器重建主要并发症的显著因素
核心结论
- 扩张器重建队列中主要并发症与临床变量存在关联,较大扩张器尺寸是失败预测因素,尤其合并放疗时。
- 直接植入重建被证明是安全的,作者描述了可靠的重建方法及即使超过500 g仍安全的植入物尺寸范围。
研究设计与样本
- 回顾性研究,样本为3年内294例即刻乳房重建。
- 比较扩张器法与直接植入(DTI)重建,DTI采用传统肌下技术的变体。
- 分析因素包括年龄、BMI、高血压、吸烟、糖尿病、乳房切除类型、植入物大小、新辅助/辅助化疗及放疗。
- 主要结局为并发症发生率,按是否需修正手术分为主要或次要。
主要发现
- DTI重建(中位随访26个月)并发症率17.2%,其中主要4.3%、次要12.8%,与临床变量无显著关联。
- 扩张器重建(中位随访19个月)并发症率18.3%,其中主要12.5%、次要5.8%。
- 单因素分析显示总体并发症与放疗显著相关(P = 0.01)。
- 主要并发症与扩张器大小(P < 0.005)、BMI(P < 0.005)及放疗(P < 0.01)显著相关,放疗与BMI在多因素分析中保留显著性。
- 新辅助/辅助化疗未影响并发症率。
临床怎么用
- 乳腺癌即刻重建选择DTI时局部安全性可接受,即使植入物超过500 g。
- 扩张器重建需关注较大扩张器尺寸、BMI及放疗对主要并发症的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: After mastectomy, immediate breast reconstruction is paramount. With the growing number of nipple-sparing mastectomies, the chances of successful one-stage reconstruction with implants are also increasing. Local safety is one of the main issues. This study investigated the factors that could lead to major or minor complications after expander-based versus direct-to-implant (DTI) reconstruction. METHODS: The studied factors were age, body mass index (BMI), hypertension, smoking, diabetes, type of mastectomy (nipple-sparing/total), implant size, neoadjuvant/adjuvant chemotherapy, and radiotherapy. The study sample included 294 immediate reconstructions over 3 years. The primary outcome was the incidence of complications, major or minor depending on the necessity of revision surgery. For the DTI pocket, we applied a variant of the conventional submuscular technique. RESULTS: In DTI reconstructions (median follow-up 26 months), the complication rate was 17.2% (4.3% major and 12.8% minor) with no significant association with clinical variables. In expander-based reconstructions (median follow-up 19 months), the complication rate was 18.3% (12.5% major and 5.8% minor). Univariate analysis showed a significant association between overall complications and radiotherapy (P = 0.01) as well as between major complications and expander size (P < 0.005), BMI (P < 0.005), and radiotherapy (P < 0.01); radiotherapy and BMI retained significance in multivariate analysis. Neoadjuvant/adjuvant chemotherapy did not affect the complication rate. CONCLUSIONS: There was evidence of an association between major complications and clinical variables in the expander-based cohort. Larger expander size was a predictor of failure, especially combined with radiation. Direct-to-implant reconstruction proved to be safe. We describe a reliable method of reconstruction and a safe range of implant sizes even beyond 500 g.
引用
- Riggio E, Toffoli E, Tartaglione C, et al. Local safety of immediate reconstruction during primary treatment of breast cancer. Direct-to-implant versus expander-based surgery. J Plast Reconstr Aesthet Surg. 2018. PMID: 30497914. doi:10.1016/j.bjps.2018.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。